Step 1
State the “add thesis” in one sentence (what changed?)
Before you add, rewrite the thesis as if this were a brand-new buy. Name what changed since the original entry: a new datapoint about demand, pricing...
Keyword: should i average down a losing stock
Use Case: Averaging Down a Losing Position Without Self-Deception
A decision gate for averaging down: require new evidence, recompute risk exposure, set a size cap, and write invalidation triggers before adding capital.
Averaging down is not “buying the dip.” It is adding capital to a thesis while pressure is rising. Use this playbook when you want to add to a losing position: require new business evidence (not just a lower price), recompute total exposure and correlation, pre-commit to a size cap, and write 1–3 invalidation triggers plus a next review date. If the thesis is broken, the balance sheet is fragile, or you cannot write the exit rule in plain language, do not add. Educational content only—not investment advice.
30-second action
Turn this page into one decision step
Pick the smallest next action now: test your bias pattern, run a scenario, or copy a prompt before making a portfolio move.
Quick Take
- State the “add thesis” in one sentence (what changed?)
- Recompute downside, concentration, and correlation (risk first)
- Pre-commit to a size cap and a finite add plan
Visual Playbook
Step 2
Recompute downside, concentration, and correlation (risk first)
Averaging down increases concentration risk and can quietly multiply correlation exposure (same sector, same factor, same macro sensitivity). Recheck...
Step 3
Pre-commit to a size cap and a finite add plan
Define the maximum total weight you are willing to own and the maximum number of adds you will allow (often one or two for most investors). Write the...
Use-Case Playbook
1) State the “add thesis” in one sentence (what changed?)
Before you add, rewrite the thesis as if this were a brand-new buy. Name what changed since the original entry: a new datapoint about demand, pricing power, unit economics, balance-sheet risk, or competitive position. If the only “change” is a lower price, you are averaging down based on emotion and anchoring. Your burden of proof is higher when you are wrong on P&L: the add needs stronger evidence than the original buy, not weaker.
2) Recompute downside, concentration, and correlation (risk first)
Averaging down increases concentration risk and can quietly multiply correlation exposure (same sector, same factor, same macro sensitivity). Recheck your max position-size policy, worst-case drawdown, liquidity needs, and what else would move together in a stress scenario. If the new size would break your risk budget in a bear case, the lower price is irrelevant. The goal is “survivable + reviewable,” not “lower average cost.”
3) Pre-commit to a size cap and a finite add plan
Define the maximum total weight you are willing to own and the maximum number of adds you will allow (often one or two for most investors). Write the plan before you buy more: what would justify the next add, what price/valuation band you consider acceptable, and what conditions would block additional capital. Open-ended averaging is a process failure because every new drop can be rationalized as “even cheaper.”
4) Write 1–3 invalidation triggers (not price stops)
An invalidation trigger is a business or risk signal that forces a pause, resize, or re-underwrite (for example: margin structure breaks, funding risk rises, demand thesis fails, management credibility deteriorates, or the competitive moat weakens). Triggers are not “down 10%.” Write the evidence you will check and the action you will take. If you cannot name what would change your mind, you are not managing risk—you are hoping.
5) Document the decision and schedule the next review date
Treat the add as a decision memo: add thesis (what changed), risk budget and max size, triggers that would block more adds, and the next review checkpoint (earnings, product launch, funding event, or a monthly review date). This is how you prevent hindsight edits. If you can’t log it cleanly, you are likely averaging down to relieve discomfort rather than to improve expected value.
Template Snapshot
Decision fields to lock before execution
- Thesis in one sentence
- Invalidation trigger and evidence threshold
- Risk budget and position-size boundary
- Review date and expected catalyst window
Action Checklist (Shareable)
- State the “add thesis” in one sentence (what changed?).
- Recompute downside, concentration, and correlation (risk first).
- Pre-commit to a size cap and a finite add plan.
- Write one invalidation trigger and one review date before you act (use: Open Risk Principles).
- Double-check the common pitfall: When should I avoid averaging down even if the stock looks “cheap”.
- Do one follow-up in 10 minutes: Use average-down prompts.
Share Kit
Why KeepRule
- Structured decision system across Scenarios, Principles, Masters, and Prompts.
- Built for repeatable execution, not one-off opinions.
- Designed for long-term investors who want fewer emotional mistakes.
Recommended KeepRule Paths
FAQ
Is averaging down usually a bad idea?
It is often a bad idea when the only argument is “it’s cheaper now.” Lower price does not fix a weaker business case, higher leverage, or a broken moat. Averaging down can be rational only when you can explain (in writing) what evidence improved, why expected value improved, and why the new position size still fits your risk budget. The goal is not to feel better about cost basis—it is to own more only when the thesis got stronger and the downside is still survivable.
What should block an average-down decision?
Block the add if any load-bearing risk moved against you: thesis confidence is lower, balance-sheet risk is higher, management credibility worsened, dilution risk increased, or your concentration/correlation caps are breached. Also block it when you cannot identify new evidence you can verify. A lower quote is not evidence. If you cannot state a clear invalidation trigger and a review date, the process is not ready for more capital.
What is a good “add thesis” versus a bad one?
A good add thesis is evidence-driven and specific: “Unit economics improved, customer retention is higher, and the bear-case downside is now smaller at this price—so I can own up to X% with trigger Y.” A bad add thesis is narrative or emotional: “It can’t go lower,” “the market is wrong,” or “I need to get back to even.” If you can’t translate the reason into measurable drivers and a time horizon, treat it as a bias signal, not an investment edge.
How many add levels are reasonable?
Keep it limited and predefined—often one or two adds for most investors. The point of a finite plan is to stop price action from rewriting your rules. Decide the maximum total weight first, then define what would justify each add (evidence and valuation band) and what would block it (triggers). If your plan is “I’ll keep adding until it turns,” that is not a plan; it is loss-chasing.
How should I document the decision?
Write the original thesis, the updated add thesis (what changed), the bear-case downside and how it impacts your portfolio, the max position-size cap, and 1–3 invalidation triggers with the next review date. Keep it short, but explicit. Documentation is not bureaucracy—it is protection against hindsight edits and impulse doubling. If you cannot write these items cleanly, the add decision is not ready.
When should I avoid averaging down even if the stock looks “cheap”?
Do not average down when the thesis is time-based hope (“eventually it rebounds”) or when the downside includes permanent impairment (funding risk, fraud risk, structural demand loss, or a broken balance sheet). Also avoid averaging down when you are already above your risk caps or when you cannot verify the facts you are relying on. Cheapness without a survivable plan is not margin of safety; it is leverage to uncertainty.
Make averaging-down rules explicit
Before your next add decision, write evidence criteria, size cap, and invalidation trigger in one checklist.